let's bring in eli lilly ceo david ricks at the healthcare conference.> good morning. >> let me express condolences about the loss of your father. >> thank you so much. >> we are stunned as usual about the fact that the stock is down. and i don't want to be too pedestrian to talk about the stock because i think you are talking about something bigger than stock. talking about something in 2025 that would be the most shocking, fastest growing drug of all time. why don't you talk about it? >> today we are putting out guidance for the year and we are excited how 25 is setting up. we exited with the business as you are referring to zepbound, mounjaro and the older one, annualizing $25 billion a your, growing 60%. that sets up a year where we are projecting for the company 32% total growth. that is about what we did last year but on a higher basis. the rest of the portfolio is doing incredibly well as well. high team growth annualizing to $20 billion. really excited about the progress of the company and 2025 is looking even brighter. >> looking even brighter b

. >> david ricks didn't do a good thing. >> i think the average analyst price is just still north of $1,000. what's the case, though, jared, if there is one, if this can break down in a meaningful way? >> what's going on? yeah. i think the valuation is still the biggestcology straint. it's trading 20, 25 times. and north of 25 times, 2026. obviously, that pales in comparison to where the stock traded last year, at this time. but it's still much higher than most of the other pharmacompanies out there. does it break down? i think you need to see a couple quarters where the numbers do not inflect higher. this quarter, zepbound missed numbers. man jara missed numbers. again, we're talking about a very small variance. but in order for this stock to break down from here. i think you need to see a couple of quarter, where you really are starting to see evidence that the revenue is not meeting consensus. >> jared, do you think that they diversify away from the fat loss, drugs, and they go with another area? or do they gobble up the smaller players? dipped below $500 million market cap. this

ceo david ricks told jim cramer that this is not about a slowdown in demand. >> we are doing somethingever done. we have growing a pharmaceutical product at a rate and scale that really is new for us and new for the industry. we will get some things wrong and we have. we saw destocking in the channel in the second half. we put that into the forward outlook. we don't expect it to come back. we have seen ups and downs in various parts of the market. people switching between the diabetes and obesity form. prediction has been tougher but the underlying fundamentals are incredible. >> we are seeing all of the obesity names down like novo and viking. they are all getting hit on this. a lot of outstanding questions hoar. >> appreciate you bringing that report for us. >>> ahead, meta shares are slipping in today's session, what is behind the drop and what it may mean for the rest of the social stocks as well. we are back on the bell after this break. >>> sector sort is sponsored by sector spider etfs. >>> visit us on the web at sector spiders.com. ah, this one lets me adjust the bass. add more

sitting down with david ricks. pleased to say david joins us for more. welcome to the program. fantastic leader. what did he have to say to you this time around? david: dave ricks is the c.e.o. of eli lilly, started in 1876. a respectable drug company, pharmaceutical company. in the five years that he has been the c.e.o., the stock is up about nine times. that's in part because of the glp-1 drug they have called zepbound. they have mounjaro for diabetes. these are the weight loss drugs we have been talking about. it's amazing what's happened in the pharmaceutical industry. eli lilly was -- eli lilly was always a successful. it is now like tonight first pharmaceutical company in the world to have a market capitalization of $1 trillion. it's now about $900 billion or so. this is because people wanted to lose weight. roughly 70% of the people in the united states are overweight. and amazingly 40% are defined as owe bees. of -- obese. this drug tends to reduce your appetite and a beneficial impact. it seems it might also have a beneficial impact on other related problems that peopl

. >> david: the non-profit wings of rescue flying shelter pets out of the fire zone to safety. hazel, sergio, magood, archie. ricks inside the plane. >> hi, david. in the past two days we've flown flights carrying 200 pets to shelters in the pacific northwest. we have at least eight more flights on tap. >> david: 86 shelter pets sent to utah, six to oregon, 70 flown to seattle. pilots felipe morales and justin schneider with the puppies hoping to find them homes elsewhere. >> if your viewers would like to help us save even more pets go to www.wingsofrescue.org/donate. thank you so much. >> david: so many of you saw the image captured by our team in altadena. a lost dog standing by this firefighter as he battled the flames, max, separated from his family in the eaton fire. dog trainer of clutch canine in whittier, california, called in to help taking in max. his family has been found tonight. >> i'll go and take him to our facility. get him food and get him water and reunite him with his owners. max is doing well and his family preparing for his safe return. the firefighter who comforted max. >> hi, everyone. >> d

david: was that the intention when the drug was developed? rick we launched the first gp-1 : medication in the world in 2005. it was a twice daily injection for people with diabetes. that was the effort. on the cover of our next report is a woman using the drug. she said my diabetes is under control and i'm losing some weight. 2006. the cover of the annual report. we had to improve the medicines to really make them effective for weight loss. one big improvement was to make them weekly, that's a convenience benefit, but even more important, the action of the medicine flatter, being more consistent through the day and night. when we had it twice a day there were ups and down. one effect of glp-1 medications, they cause nausea and g.i. distress. that is a function of the up and down in your system. when it was weekly, it was dosed -- it was flatter and we could does higher and the changes were flatter, so made it better for weight loss. that was an accidental breakthrough of trying to make a convenient form. david: there's another company in sort of

rick: this got really hard. so much more difficult. [laughter] wait, yeah. see you tomorrow. davidmping up as new evid

rick: this got really hard. so much more difficult. [laughter] wait, yeah. see you tomorrow. david: fox on top of the new orleans terror attack the probe a ramping up as new evidence is uncovered. and how the the city is hit with hits first lawsuit in the wake of that attack. reaction from louisiana attorney general is here. and that dramatic battle for the gavel might be over after mike johnson is reelected house speaker. but does the rocky road it took to get there signal trouble for republicans' very slim majority? house freedom caucus chair andy harris is with us and new york republican congressman mike lawler. they will weigh in. plus, what a new york judge is suggesting about president-elect donald trump's sentencing only days before his inauguration. and a live look from georgia as the first phase of president jimmy carter's memorial services begin today. welcome; everyone. happy weekend. i'm david asman, and you are watching "fox news live." we begin with madison scarpino in new orleans with the latest on the new year's terror attack and the if first lawsuit that's been fil